A traditional Chinese medicine composition for preventing and treating osteoporosis and its preparation method

Abstract

The present invention provides a medicinal and edible composition for preventing and treating osteoporosis and a preparation method thereof. The raw materials of the medicinal and edible composition are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Chinese yam, 15-20 parts of Astragalus root, 3-10 parts of Chinese angelica root, and 10-20 parts of Eucommia ulmoides leaves; the medicinal and edible composition of the present invention increases osteoprotegerin, reduces type I collagen C-terminal peptide and tartrate-resistant acid phosphatase, thereby promoting osteoblast differentiation, inhibiting osteoclast resorption, regulating bone metabolism balance, increasing femoral maximum load, and improving bone density and bone strength. The medicinal and edible composition of the present invention is highly safe and can be developed into medicines, health products, or functional foods for the prevention and treatment of osteoporosis.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a medicine-food composition for preventing and treating osteoporosis and a preparation method thereof. Background Art

[0002] Osteoporosis is a systemic bone disease caused by a variety of factors, resulting in decreased bone density and quality, disrupted bone microarchitecture, increased bone brittleness, and increased susceptibility to fracture. The core pathogenesis of osteoporosis is that various pathogenic factors affect one or more stages of bone formation or remodeling, causing bone resorption to exceed bone formation, resulting in decreased bone density.

[0003] Western medicine considers bone density (BMD), or "bone mineral density," to be a key marker of bone quality, reflecting the degree of osteoporosis and serving as a key predictor of fracture risk. Clinically, osteoporosis is often treated with antiresorptive drugs, which inhibit bone resorption and thereby increase BMD. However, these drugs have drawbacks such as a single target, severe drug dependency, significant side effects, and high cost. For example, long-term use of alendronate sodium may lead to adverse reactions such as atypical femoral fractures and mandibular osteonecrosis.

[0004] In traditional Chinese medicine, osteoporosis is classified into the categories of "bone atrophy", "bone numbness" and "bone withering". It is based on kidney essence deficiency and bone marrow reduction, and manifests as blood stasis and obstruction, and loss of bone vascular nourishment. The treatment principle is to mainly tonify the kidney and replenish essence, supplemented by strengthening the spleen and replenishing qi, promoting blood circulation and removing blood stasis, so as to regulate the dynamic balance of bone metabolism and achieve the purpose of preventing and treating osteoporosis.

[0005] By inhibiting bone resorption while promoting bone formation and regulating the dynamic balance of bone metabolism, it is possible to increase bone density, increase its maximum load, and enhance fracture resistance. Numerous studies have demonstrated that traditional Chinese medicine can not only inhibit bone resorption but also promote bone formation and regulate the dynamic balance of bone metabolism, thereby increasing bone density and enhancing fracture resistance. While traditional Chinese medicines have achieved some success in preventing and treating osteoporosis, the formulation of traditional Chinese medicine compounds relies heavily on the researcher's own experience, leading to issues such as unclear dosing patterns and time-consuming and labor-intensive drug screening.

[0006] Therefore, people hope to improve bone density, enhance bone strength, and enhance anti-fracture ability through a combination of medicine and food, thereby preventing and treating osteoporosis, and develop a product with significant efficacy, low price, and high safety. Summary of the Invention

[0007] In view of the above deficiencies in the prior art, the present invention provides a medicine-food composition for preventing and treating osteoporosis and a preparation method thereof. The medicine-food composition of the present invention can regulate the dynamic balance of bone metabolism, improve bone strength, and enhance its anti-fracture ability, thereby preventing and treating osteoporosis.

[0008] To achieve the above purpose, the specific technical solutions of the present invention are as follows:

[0009] In a first aspect, the present invention provides a medicinal and edible composition for preventing and treating osteoporosis, the raw materials of which are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Chinese yam, 15-20 parts of Astragalus root, 3-10 parts of Chinese angelica root, and 10-20 parts of Eucommia ulmoides leaves.

[0010] The present invention is based on network pharmacology research and follows the principle of monarch, minister, assistant and envoy. Radix Rehmanniae, Fructus Corni and Rhizoma Dioscoreae are used as monarch drugs, and Radix Astragali and Radix Angelicae Sinensis are used as ministers to invigorate qi and nourish blood; eucommia ulmoides leaves are used as adjuvants to nourish the liver and kidneys, strengthen tendons and bones; in this way, the effects of invigorating qi and nourishing blood, warming yang and tonifying the kidneys, replenishing blood and essence, and nourishing tendons and bones are achieved, so as to prevent and treat osteoporosis. Therefore, the present invention uses traditional Chinese medicines including Radix Rehmanniae, Fructus Corni, Rhizoma Dioscoreae, Radix Astragali, Radix Angelicae Sinensis and Fructus Eucommiae as raw materials to prepare a medicine-food combination. By adjusting the ratio between the raw materials, the prepared medicine-food combination can improve bone density, regulate osteoblast differentiation, inhibit osteoclast absorption, increase the maximum load of bone, enhance anti-fracture ability, and thus can be applied to the prevention and treatment of osteoporosis, effectively improving osteoporosis.

[0011] In a second aspect, the present invention provides a method for preparing the medicinal and edible composition for preventing and treating osteoporosis, comprising the following steps: weighing each component according to a proportion, soaking for 1 to 2 hours, decocting 2 to 3 times, combining the medicinal liquids obtained by multiple decoctions, and concentrating and drying the medicinal liquids to obtain the medicinal and edible composition.

[0012] In a third aspect, the present invention provides use of the medicine-food composition in preparing a product for preventing and treating osteoporosis.

[0013] The medicine-food composition increases osteoprotegerin (BGP), decreases type I collagen C-terminal peptide (CTX-I) and tartrate-resistant acid phosphatase (TRAP), regulates the dynamic balance of bone metabolism, improves bone strength, and enhances its anti-fracture ability, thereby preventing and treating osteoporosis.

[0014] In a fourth aspect, the present invention provides a traditional Chinese medicine preparation for preventing and treating osteoporosis, wherein the traditional Chinese medicine preparation comprises the medicine-food composition.

[0015] Furthermore, the dosage forms of the Chinese medicine preparation include but are not limited to decoctions, tablets, powders, powders, pills, granules, oral liquids, and capsules.

[0016] In a fifth aspect, the present invention provides a health product for improving bone density and bone strength, wherein the health product comprises the medicine-food composition.

[0017] Furthermore, the health care products include but are not limited to beverages or granules.

[0018] Compared with the prior art, the present invention is beneficial in that:

[0019] The present invention uses an animal model for pharmacodynamic evaluation to reveal the therapeutic effect of the medicinal and edible composition on osteoporosis. The medicinal and edible composition can regulate bone metabolism dynamic balance, improve bone strength, and enhance its fracture resistance by increasing osteoprotegerin, reducing type I collagen C-terminal peptide and tartrate-resistant acid phosphatase, thereby preventing and treating osteoporosis. It is highly safe and suitable for long-term use. The present invention provides a strong scientific basis for the rational use of drugs in the clinical treatment of osteoporosis and lays a foundation for the development of anti-osteoporosis drugs, health products, and functional foods. DETAILED DESCRIPTION

[0020] The technical solutions of the present invention are described clearly and completely below. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. All other embodiments obtained by persons of ordinary skill in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0021] The invention provides a medicine-food composition for preventing and treating osteoporosis. The raw materials are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Chinese yam, 15-20 parts of Astragalus root, 3-10 parts of Chinese angelica root and 10-20 parts of Eucommia ulmoides leaves.

[0022] Formula analysis

[0023] 1. Collection and screening of traditional Chinese medicines for osteoporosis

[0024] Using the keywords "kidney deficiency and marrow deficiency," "bone arthritis," and "bone atrophy," we searched databases such as the "Chinese Herbal Formula Preparations," the "National Compilation of Chinese Patent Medicine Standards," the China National Knowledge Infrastructure (CNKI) Academic Journal Full-text Database, Web of Science, and the Wanfang Data Knowledge Service Platform, yielding a total of 75 prescriptions. Excluding the following prescriptions: single-drug preparations; duplicate prescriptions with the same composition but different dosage forms, only one of which was retained; and prescriptions with inconsistent efficacy and indications. After sorting, a total of 58 prescriptions were found. The names of Chinese medicinal materials in prescriptions were standardized with reference to the 2020 edition of the Chinese Pharmacopoeia (Volume 1), "Chinese Materia Medica": ① Processed products were renamed according to the raw medicinal name, for example, salt Eucommia ulmoides, cotton Eucommia ulmoides, Eucommia ulmoides charcoal, Sichuan Eucommia ulmoides, and raw Eucommia ulmoides were standardized as Eucommia ulmoides; ② Chinese herbal aliases and common names were standardized as standard names, for example, Radix Smilax glabrae was standardized as Radix Smilax glabrae; ③ Raw material extracts were uniformly named according to the raw material, for example, compound Eucommia ulmoides fluid extract was standardized as Eucommia ulmoides; and ④ Excipient names were deleted, for example, magnesium stearate.

[0025] 1.1 Medication frequency statistics

[0026] The 58 qualified prescriptions contained a total of 201 Chinese medicinal materials. The frequency of use was recorded as the number of times each Chinese medicinal material appeared. The total frequency of use was 842 times. The top ten Chinese medicinal materials with the highest frequency of use were: Rehmannia root, Cuscuta seed, Lycium barbarum, Chinese yam, Eucommia bark, Achyranthes bidentata, Epimedium, Chinese angelica root, Poria cocos, and Cornus officinalis, as shown in Table 1.

[0027] Table 1: Frequency distribution of Chinese patent medicines for osteoporosis

[0028]

[0029] 1.2 Statistics of drug categories

[0030] With reference to the Clinical Chinese Materia Medica, statistics on the categories of Chinese medicine were conducted. There are 8 categories of Chinese medicines in total in terms of the top 40 most frequently used Chinese medicines. Most of the Chinese medicines used are tonics (frequency 353, accounting for 63.83%); followed by astringents (frequency 44, accounting for 7.96%); and then blood-activating and stasis-removing medicines, heat-clearing medicines, and diuretic and dampness-removing medicines (frequency 40, accounting for 7.32%; frequency 35, accounting for 6.33%; frequency 31, accounting for 5.61%), see Table 2.

[0031] Table 2: Distribution of the top 40 traditional Chinese medicines for osteoporosis by medication category

[0032]

[0033] 1.3 Statistics of medicinal properties and meridians

[0034] Based on the 2020 Pharmacopoeia, a statistical analysis of drug classification, properties, flavors, and meridians revealed that warming drugs were the most common (22 categories, 314 frequency, accounting for 57.83%), followed by neutral drugs (8 categories, 139 frequency, accounting for 25.60%). Sweet flavors were predominant, accounting for 45.49%, followed by bitter, accounting for 16.44%. The majority of meridians were associated with the kidney, accounting for 34.38%, followed by the liver, accounting for 25.46%, and finally the spleen, accounting for 13.75% (see Table 3).

[0035] Table 3: Distribution of neutral flavor and meridians of traditional Chinese medicines for osteoporosis

[0036]

[0037] 2. Association rule analysis

[0038] Using language, we performed an Apriori algorithm analysis on traditional Chinese medicine formulas for osteoporosis. Association analysis was performed using criteria with support ≥ 0.2 and confidence ≥ 0.8. Two association rules showed that the combination of Chinese yam → Rehmannia glutinosa had a support of 34.48%, a confidence of 0.87, and a lift of 1.441. Three association rules showed that the combinations of Rehmannia glutinosa + Cornus officinalis + Chinese yam, Rehmannia glutinosa + Poria cocos + Chinese yam, and Lycium barbarum + Rehmannia glutinosa + Chinese yam all had high support, confidence, and lift (see Table 4).

[0039] Table 4: Association rule analysis of traditional Chinese medicines for osteoporosis

[0040]

[0041] 3. Formula

[0042] The results of association rule analysis are used as the main medicine, and astragalus and angelica are used as auxiliary medicine to nourish qi and blood; eucommia leaves are used as auxiliary medicine to nourish the liver and kidneys and strengthen tendons and bones; in this way, qi and blood are nourished, yang is warmed and kidneys are nourished, blood is replenished and essence is abundant, tendons and bones are nourished, so as to achieve the purpose of treating osteoporosis.

[0043] Three candidate formulas were obtained, including combination 1: Rehmannia root - Cornus officinalis - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves; combination 2: Rehmannia root - Poria root - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves; combination 3: Rehmannia root - Lycium barbarum - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves.

[0044] 4. Network Pharmacology Prediction Analysis

[0045] The ingredient targets were predicted using databases such as TCMSP and SwissTargetPrediction, and the medicinal material targets were obtained after removing duplicates.

[0046] Using the keyword "osteoporosis" to search for osteoporosis-related disease targets in the GeneCard and OMIM databases, 233 highly correlated targets were identified. Using the Venny 2.1.0 platform, the intersection of medicinal material targets and disease targets was visualized and analyzed. The results showed that combination 1 identified 71 potential targets, combination 2 identified 65 potential targets, and combination 3 identified 66 potential targets. Combination 1 had the most targeted targets, with a coverage rate of 10.6%, indicating that combination 1 has significant potential for the prevention and treatment of osteoporosis (see Table 5).

[0047] Table 5: Network pharmacology target prediction analysis of different formulas

[0048]

[0049] Example 1

[0050] A medicinal and edible composition for preventing and treating osteoporosis is prepared by the following method: preparing Rehmannia root, Cornus officinalis, Chinese yam, Astragalus root, Chinese angelica root, and Eucommia ulmoides leaf in a weight ratio of 24:12:12:20:10:20, adding 8 times the weight of water as the raw materials and soaking for 1 hour, then decocting twice at 100°C for 1 hour each time, finally combining the two decoctions, concentrating, and freeze-drying to obtain the medicinal and edible composition 1.

[0051] Example 2

[0052] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method being as follows: preparing rehmannia root, cornus officinalis, yam, astragalus, angelica, eucommia bark, and antler powder in a weight ratio of 18:15:18:15:3:15, adding 12 times the weight of the raw materials in water and soaking for 2 hours, then decocting twice at 100°C for 1 hour each time, finally combining the two decoctions, concentrating, and drying to obtain the medicinal and edible composition 2.

[0053] Example 3

[0054] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method being as follows: preparing rehmannia root, cornus officinalis, yam, astragalus root, angelica root, and eucommia ulmoides leaf in a weight ratio of 20:13:12:18:8:10, adding 12 times the weight of water as the raw materials and soaking for 1 hour, then decocting at 100°C three times for 1 hour each time, finally combining the two decoctions, concentrating, and drying to obtain the medicinal and edible composition 3.

[0055] Example 4

[0056] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method being as follows: preparing Rehmannia root, Cornus officinalis, Chinese yam, Astragalus root, Chinese angelica root, and Eucommia ulmoides leaf in a weight ratio of 15:15:20:18:10:15, adding 8 times the weight of the raw materials in water and soaking for 1 hour, then decocting twice at 100°C for 1 hour each time, finally combining the two decoctions, concentrating, and drying to obtain a medicinal and edible composition 4.

[0057] Comparative Example 1

[0058] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method being as follows: preparing Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, and Chinese angelica in a weight ratio of 24:12:12:20:10, adding 8 times the weight of the raw materials in water and soaking for 1 hour, then decocting twice at 100°C for 1 hour each time, finally combining the two decoctions, concentrating, and freeze-drying to obtain the medicinal and edible composition 5.

[0059] Comparative Example 2

[0060] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, and Eucommia ulmoides leaves are mixed in a weight ratio of 24:12:12:20:20, 8 times the weight of the raw materials are added with water and soaked for 1 hour, then decocted twice at 100°C for 1 hour each time, and finally the two decoctions are combined, concentrated, and freeze-dried to obtain the medicinal and edible composition 6.

[0061] Comparative Example 3

[0062] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method being as follows: preparing Rehmannia root, Cornus officinalis, Chinese yam, Chinese angelica, and Eucommia ulmoides leaves in a weight ratio of 24:12:12:10:20, adding 8 times the weight of water as the raw materials and soaking for 1 hour, then decocting twice at 100°C for 1 hour each time, finally combining the two decoctions, concentrating, and freeze-drying to obtain the medicinal and edible composition 7.

[0063] The medicinal and edible compositions prepared in Examples 1-4 and Comparative Examples 1-3 were subjected to pharmacodynamic tests.

[0064] 1. Experimental animals: 12-week-old female SD rats (purchased from Hubei Provincial Center for Disease Control and Prevention) were selected and fed adaptively for one week before animal experiments.

[0065] 2. Experimental methods

[0066] Modeling and grouping: 77 13-week-old female SD rats were divided into two groups, a sham-operated control group of 7 rats (normal group) and an ovariectomy group of 70 rats. They were treated with antibiotics one week after surgery and had free access to water and diet for 12 weeks to complete the model construction.

[0067] 3. Dosage and grouping: Ovariectomized rats were divided into model group, positive Western medicine group, positive Chinese medicine group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, control group 1, control group 2, and control group 3. Each rat was gavaged with 1 mL / 100 g of the drug. The specific dosing groups were as follows:

[0068] Normal group: gavage with equal dose of pure water;

[0069] Model group: gavage with equal dose of pure water;

[0070] Positive Western medicine group: alendronate sodium 6.3 mg / kg;

[0071] Positive Chinese medicine group: Gushukang granules 1.8 g / kg;

[0072] Test group 1: 2.5 g / kg of the medicinal and edible composition prepared in Example 1;

[0073] Test group 2: 2.5 g / kg of the medicinal and edible composition prepared in Example 2;

[0074] Test group 3: 2.5 g / kg of the medicinal and edible composition prepared in Example 3;

[0075] Test group 4: 2.5 g / kg of the medicinal and edible composition prepared in Example 4;

[0076] Control group 1: 2.5 g / kg of the medicine-food composition prepared in Comparative Example 1;

[0077] Control group 2: 2.5 g / kg of the medicinal and edible composition prepared in Comparative Example 2;

[0078] Control group 3: 2.5 g / kg of the medicine-food composition prepared in Comparative Example 3.

[0079] After the last administration, blood was collected from the abdominal cavity and serum was collected after centrifugation. The right leg was fixed with paraformaldehyde and the left leg femoral tissue was stored in a -80°C refrigerator for subsequent testing of relevant indicators.

[0080] 4. Experimental results

[0081] 4.1 The liver and kidney functions were tested. The results are shown in Table 6. No obvious abnormalities were found, indicating that the medicine-food composition of the present invention is highly safe.

[0082] Table 6: Changes in liver and kidney function in rats of each group

[0083]

[0084] 4.2 Comparison of bone density among rat groups

[0085] Bone density measurement can help diagnose osteoporosis. Currently, bone density is the most effective predictor of fracture risk, and fracture risk is geometrically related to bone density. In this experiment, the right femur of the rat in the experimental case was scanned using the viva CT80 small animal scanning system (SCANCO Medical AG). The rat femur was fixed on the stage. The distal femur was scanned along the long axis of the rat femur at a 360° scanning angle and a scanning resolution of 10 μm. After the scan, the corresponding area was selected on the host computer, and the system's built-in imaging analysis software was used to perform 3D reconstruction and analyze and statistically analyze the relevant data. The results are shown in Table 7. The bone density of rats in the model group decreased significantly, while the bone density of all drug-treated groups increased. The effect of Group 1 was comparable to that of the positive Chinese medicine.

[0086] Table 7: Changes in bone density of rats in each group

[0087]

[0088] Note: Compared with the normal group, #indicates P < 0.05; ## indicates P < 0.01; ### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Indicates P < 0.001.

[0089] 4.3 Changes of bone metabolism markers in serum of rats in each group

[0090] Bone metabolism balance is achieved through the interaction and mutual checks and balances between osteoblasts and osteoclasts, and is crucial for maintaining the normal function of the skeletal system. The results of serum bone metabolism markers in rats from each group are shown in Table 8. All drug-treated groups were able to regulate bone metabolism. Among them, Group 1 significantly downregulated the expression levels of CTX-I and TRAP, comparable to the positive Chinese medicine group. The positive Western medicine group had the most significant effect in downregulating the expression levels of CTX-I and TRAP, indicating that it optimally inhibited osteoclast activity. Group 1 significantly upregulated the expression level of BGP, indicating its strong ability to promote osteoblast formation.

[0091] Table 8: Changes of bone metabolism markers in rats in each group

[0092]

[0093] Note: Compared with the normal group, # indicates P < 0.05; ## indicates P < 0.01; ### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Indicates P < 0.001.

[0094] 4.4 Comparison of bone biomechanics in rats of each group

[0095] The results of bone biomechanical tests of rats in each group are shown in Table 9. It can be seen from Table 9 that compared with the normal group, the maximum load of rats in the model group was significantly reduced, and the maximum load of each drug-treated group increased to varying degrees, among which the improvement effect of test group 1 was the best, indicating that it has an excellent effect in preventing fracture risks.

[0096] Table 9: Changes in the maximum load of femur of rats in each group

[0097]

[0098] Note: Compared with the normal group, # indicates P < 0.05; ## indicates P < 0.01;### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Indicates P < 0.001.

[0099] In summary, the medicinal and edible composition prepared from raw materials including Rehmannia glutinosa, Cornus officinalis, Chinese yam, Astragalus membranaceus, Chinese angelica and Eucommia ulmoides leaves can improve bone density, regulate osteoblast differentiation, inhibit osteoclast absorption, increase the maximum load of bone, enhance anti-fracture ability, thereby effectively improving osteoporosis. Moreover, it has high safety and can be used for the prevention and treatment of osteoporosis.

[0100] The above specific embodiments describe the implementation of the present invention in detail, but the present invention is not limited to the specific details of the above embodiments. Within the scope of the claims and technical concept of the present invention, various simple modifications and changes can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for preventing and treating osteoporosis, characterized in that: The raw materials are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Chinese yam, 15-20 parts of Astragalus root, 3-10 parts of Chinese angelica root and 10-20 parts of Eucommia ulmoides leaves.

2. A method for preparing the Chinese medicine composition according to claim 1, characterized in that: The method comprises the following steps: weighing raw materials, soaking for 1-2 hours, decocting for 2-3 times, combining medicinal liquids obtained by multiple decoctions, and concentrating and drying the medicinal liquids to obtain a traditional Chinese medicine composition.

3. Use of the traditional Chinese medicine composition according to claim 1 or the traditional Chinese medicine composition prepared by the method according to claim 2 in the preparation of a medicament for preventing and treating osteoporosis.

4. A Chinese medicine preparation for preventing and treating osteoporosis, characterized in that: The traditional Chinese medicine preparation comprises the traditional Chinese medicine composition according to claim 1 or the traditional Chinese medicine composition prepared by the method according to claim 2.

5. The Chinese medicine preparation according to claim 4, characterized in that The dosage forms of the Chinese medicine preparation include decoction, tablets, powders, powders, pills, granules, oral liquids and capsules.

6. A health food that helps improve bone density, characterized in that: The health food comprises the traditional Chinese medicine composition according to claim 1 or the traditional Chinese medicine composition prepared by the method according to claim 2.

7. The health food according to claim 6, characterized in that The health food includes beverages or granules.

Images